Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Diabetes Foundation, Device Firms Partner To Develop Artificial Pancreas

This article was originally published in The Gray Sheet

Executive Summary

The Juvenile Diabetes Research Foundation has begun partnering with device companies to speed the commercialization of artificial pancreas technology that would take some of the guesswork out of diabetes management

You may also be interested in...

One Study Down, Three To Go On Animas’ First-Gen Artificial Pancreas Project

Following a successful feasibility study, the J&J unit still has multiple clinical milestones to hit before it can put its closed-loop diabetes treatment system up for market approval.

Research In Brief

Artificial pancreas feasibility, computed tomography cancer risk documentation and more data updates.

Diabetes Researchers Say FDA Is Slowing Artificial Pancreas Efforts

Developers of "artificial pancreas" devices for treating type 1 diabetes may gain insight from new FDA draft guidance on clinical trial design, but patients and advocates say the agency is standing in the way of greater advances in the space.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts